Christopher Jones, MD
Hematology & Oncology · Thornton, CONPI 1700876992
Payments from drug & device makers
Across 70 payments — averaging $53.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$2K
- Genentech USA, Inc.$154
- Johnson & Johnson$150
- Amgen$141
- Seagen Inc.$99
- Astellas Pharma US Inc$93
- plus $917 from 33 others
What the payments were for
- Speaking & faculty fees$1,98052%
- Food & beverage$1,39637%
- Education$39611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 3 | $2,219 |
| Genentech USA, Inc. | 9 | $154 |
| Johnson & Johnson | 2 | $150 |
| Amgen | 3 | $141 |
| Seagen Inc. | 1 | $99 |
| Astellas Pharma US Inc | 4 | $93 |
| Novartis | 4 | $73 |
| Merck | 5 | $73 |
| Gilead | 4 | $66 |
| Bristol Myers Squibb | 2 | $43 |
| Myriad Genetic Laboratories, Inc. | 1 | $43 |
| Sanofi | 2 | $42 |
| Verastem, Inc. | 2 | $34 |
| Stryker | 1 | $33 |
| AstraZeneca | 2 | $32 |
| Karyopharm Therapeutics Inc. | 1 | $30 |
| Sobi, Inc | 1 | $28 |
| Tesaro, Inc. | 1 | $27 |
| Mylan Institutional Inc. | 1 | $26 |
| Pfizer | 2 | $25 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Shionogi Inc | 1 | $17 |
| GSK | 1 | $17 |
| EMD Serono, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AYVAKIT$2,110
How this compares
$3,772 in reported general payments places this provider in the 35th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 19 | $303,107 |
| ImbruvicaIbrutinib | 21 | $293,510 |
| IbrancePalbociclib | 13 | $206,545 |
| NubeqaDarolutamide | 12 | $163,716 |
| EliquisApixaban | 26 | $37,495 |
| XareltoRivaroxaban | 13 | $8,979 |
| Abiraterone Acetate | 11 | $1,433 |
| Anastrozole | 39 | $952 |
| Hydroxyurea | 24 | $622 |
| Ondansetron Hcl | 42 | $503 |
| Dexamethasone | 22 | $496 |
| Letrozole | 12 | $444 |
| Prochlorperazine Maleate | 31 | $366 |
| Mirtazapine | 16 | $271 |
| Acyclovir | 32 | $232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $19 | $293,51021 claims |
| PfizerIbrance, Eliquis | $25 | $244,04039 claims |
| Johnson & JohnsonXarelto | $150 | $8,97913 claims |
| Lilly USA, LLCOlanzapine | $21 | $9017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Thornton
- David AndorskyBoulder$31.5M
- John BurkeAurora$25.4M
- Elena ShagisultanovaAurora$22.4M
- Allen CohnDenver$13.5M
- Elaine LamAurora$12.6M
- Robert RifkinDenver$11.3M
- Robert JotteLone Tree$9.4M
- Daniel PollyeaAurora$9.4M
- Henning SchadeDenver$9M
- Manali KamdarAurora$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.